First Pacific Advisors LP Makes New $35.43 Million Investment in Thermo Fisher Scientific Inc. $TMO

First Pacific Advisors LP bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, Holdings Channel.com reports. The firm bought 87,370 shares of the medical research company’s stock, valued at approximately $35,425,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. New York Life Investment Management LLC grew its holdings in shares of Thermo Fisher Scientific by 0.4% during the 2nd quarter. New York Life Investment Management LLC now owns 51,393 shares of the medical research company’s stock worth $20,838,000 after acquiring an additional 214 shares during the period. Private Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 7.2% during the 2nd quarter. Private Wealth Partners LLC now owns 64,700 shares of the medical research company’s stock worth $26,233,000 after acquiring an additional 4,342 shares during the period. Howard Capital Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 29.0% during the 2nd quarter. Howard Capital Management Inc. now owns 2,979 shares of the medical research company’s stock worth $1,209,000 after acquiring an additional 670 shares during the period. Purkiss Capital Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 52.3% during the 2nd quarter. Purkiss Capital Advisors LLC now owns 3,455 shares of the medical research company’s stock worth $1,401,000 after acquiring an additional 1,186 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in shares of Thermo Fisher Scientific by 1.0% during the 2nd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 2,740 shares of the medical research company’s stock worth $1,111,000 after acquiring an additional 28 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the topic of a number of research analyst reports. Morgan Stanley upped their target price on Thermo Fisher Scientific from $560.00 to $656.00 and gave the stock an “overweight” rating in a report on Tuesday. Cowen reissued a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. TD Cowen boosted their price target on Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. William Blair assumed coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating on the stock. Finally, Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Nineteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $594.65.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $558.18 on Wednesday. The stock has a market capitalization of $210.77 billion, a PE ratio of 32.25, a price-to-earnings-growth ratio of 3.30 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The stock’s 50 day simple moving average is $506.77 and its 200 day simple moving average is $455.26.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the firm posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 17,104 shares of the company’s stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $573.54, for a total value of $9,809,828.16. Following the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $65,247,057.48. This represents a 13.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the transaction, the executive vice president directly owned 21,152 shares in the company, valued at $12,144,420.80. The trade was a 1.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 54,420 shares of company stock valued at $28,134,684. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.